March is Cancer Colon Awareness month and a new publication in The New England Journal of Medicine reinforces the efficacy of a blood test for #ColorectalCancer screening in people of average risk. Our DDM team is proud to have participated in the ECLIPSE trial, one of the largest studies of its kind. Research results demonstrate that “In an average-risk screening population, this cfDNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions.” We thank all of our wonderful patients who participated in this study.